Skip to main content

Orchid Reports Slight Revenue Increase, Narrowing Losses

NEW YORK, Feb. 26 (GenomeWeb News) - Orchid BioSciences recorded slightly increased revenues and narrowing losses for the fourth quarter of 2003, the company said today.


Revenues were $13.7 million, up from $13 million during the same period a year ago.


R&D costs decreased sharply, to $0.2 million, from $3 million during the fourth quarter of 2002. This is primarily a result of Orchid's divesture of its SNP genotyping instrumentation business, and of strategic changes of its GeneShield business, according to the company.


The company's net loss amounted to $7.3 million, or $.09 per share, down from $35.1 million, or $.63 per share, during the year-ago period.


As of Dec. 31, Orchid had $9.9 million in cash and cash equivalents.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.